SHANGHAI, June 30 (Reuters) – Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.
Lilly will continue manufacturing, supplying and developing the drug, it said in a statement.
(Reporting by Andrew Silver in Shanghai; Editing by Christian Schmollinger)
Brought to you by www.srnnews.com